ArticleCanadian liver journal2025
Increased Alkaline Phosphatase Associated with Brown Algae and Mushroom Extract-Containing Supplement Use.
Article in Canadian liver journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Marked alkaline phosphatase (ALP) elevation as a consequence of drug exposure is uncommon. We report a chronic hepatitis B virus (HBV) positive 47-year-old male patient taking a brown algae and mushroom extract-containing supplement (Umi No Shizuku) with ALP levels almost 7 times the upper limit during routine bloodwork. ALP was 991 U/L (normal 50-112 U/L). All other liver studies were within normal range: alanine aminotransferase (ALT) 32 U/L (normal 10-63 U/L), aspartate aminotransferase (AST) 25 U/L (normal 12-41 U/L), gamma-glutamyl transferase (GGT) 22 U/L (normal 11-105 U/L), and total bilirubin 13 µmol/L (normal ≤ 13 µmol/L). Methods: Serial bloodwork was conducted to assess liver studies and bone disease markers. Imaging was utilized to exclude liver and bone disease. Results: Bloodwork and imaging all returned values within the normal range. Interrupting the supplement led to rapid normalization of ALP blood levels in the patient. Conclusions: The supplement was the only variable changed in this case, leading us to suspect that it was responsible for the elevated ALP levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.